Elite Pharmaceuticals Inc (ELTP)

[Couch]

For those who want to know the real deal and why $2 is in the works as I type. $$$$$$$$$$


ROUNDTABLE DISCUSSION: Reformulating Opioids to Deter Abuse - See more at: http://www.drug-dev.com/Main/Back-Issues/ROUNDTABLE-DISCUSSION-Reformulating-Opioids-to-Det-648.aspx#sthash.uubQyJ4l.dpuf

http://www.drug-dev.com/Main/Back-Issues/ROUNDTABLE-DISCUSSION-Reformulating-Opioids-to-Det-648.aspx

Mr. Hakim: I do not believe the “limitation of use” labeling language will drive physicians to switch from extended-release opioids to immediate-release opioids. I believe the vast majority of physicians already understand both the benefits and shortcomings of extended-release and immediate-release opioids and prescribing will continue to be driven by what is best for the patient. Given all considerations, I believe extended-release opioids will continue to be the primary choice for chronic pain.

YOU see Nasrat has had an immediate release ADT in the works for some time now. Again, $$$$$$$

https://clinicaltrials.gov/ct2/show/NCT02401750?term=%22Elite+Laboratories%2C+Inc%22&rank=2

Primary Outcome Measures:
Pain Intensity Measure for Oxycodone/Naltrexone (a) [ Time Frame: Every 6 hours for 48 hours ] [ Designated as safety issue: No ]
Self reported pain intensity prior to 1st dose, every 30 minutes for the 1st 6 hours, immediately prior to each drug administration (every 6 hours) and at 2 hours after each drug administration. Each is scored 0-10 (0=no pain and 10 = worst pain imaginable) on a Likert Scale